<DOC>
	<DOCNO>NCT02342600</DOCNO>
	<brief_summary>This study evaluate combination trametinib pazopanib patient advance gastrointestinal stromal tumor ( GIST ) .</brief_summary>
	<brief_title>SARC029 : Trametinib Pazopanib Patients With GIST ( Gastrointestinal Stromal Tumor )</brief_title>
	<detailed_description>Trametinib pazopanib independently approve cancer . Both drug work inhibit tumor development different way . Combining drug may lead improved disease control . The purpose study evaluate effect combination drug advance gastrointestinal stromal tumor .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Inclusion Criteria include : Age ≥ 18 year Histologically confirm diagnosis advance GIST ECOG performance status 01 Measurable disease per modify RECIST 1.1 Prior disease progression least imatinib sunitinib . Maximum 3 prior kinase inhibitor allow treatment advanced disease . Patients prior exposure pazopanib MEK inhibitor eligible . Adequate organ system function within 14 day ( 72 hour ) prior start protocol therapy Patients must provide write informed consent prior performance studyspecific procedures assessment must willing comply treatment followup . Women childbearing potential must negative urine blood pregnancy test within 7 day Cycle 1 Day 1 . Fertile men woman childbearing potential must agree use effective contraception define Section 7 study 4 month follow last dose study drug sex . Life expectancy ≥ 3months Exclusion Criteria include : Prior malignancy . Central nervous system ( CNS ) metastases baseline , exception patient previouslytreated CNS metastasis ( surgery +/ radiotherapy , radiosurgery , gamma knife ) meet follow criterion : asymptomatic requirement steroid enzymeinducing anticonvulsant least 3 month prior screen . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding Clinically significant gastrointestinal abnormality may affect absorption investigational product QTcB interval &gt; 480 msec History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class II , III , IV congestive heart failure , define New York Heart Association ( NYHA ) Uncontrolled arrhythmias Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥ 140 mm Hg diastolic blood pressure ( DBP ) ≥ 90 mmHg ] . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Major surgery trauma within 28 day prior first dose investigational product and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major surgery ) . Evidence active bleeding bleed diathesis . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage . Recent hemoptysis ( ≥ 1/2 teaspoon red blood within 8 week first dose study drug ) Any serious unstable preexist medical , psychiatric , condition could interfere patient 's safety , provision inform consent , compliance study procedure . Unable unwilling discontinue use prohibit medication list Section 5.2.4 least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study . Treatment follow anticancer therapy : Radiation therapy tumor embolization within 14 day prior first dose OR Chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose study drug . Ipilimumab must discontinue least 8 week prior initiation treatment trametinib Administration nononcologic investigational drug within 30 day five halflives ( whichever longer ) prior first dose study drug . Any ongoing toxicity prior anticancer therapy ≥ Grade 1 and/or progress severity , except alopecia . Inability swallow retain oral medication Known suspect allergy hypersensitivity pazopanib , trametinib ( GSK1120212 ) , excipients formulation give course trial . History interstitial lung disease pneumonitis , intracardiac defibrillator , know HIV , active HBV HCV infection , history retinal vein occlusion , symptomatic untreated leptomeningeal brain metastasis spinal cord compression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>